- Curaleaf Holdings has announced that its subsidiary Curaleaf International has acquired Can4Med
- Can4Med is a pharmaceutical wholesaler that specializes in cannabinoid medications in Poland
- Poland is one of Europe’s largest patient populations seeking the medical use of cannabis
- Shares of Curaleaf Holdings are up 4.93 per cent to C$7.66 as of 11:47 am ET
Curaleaf Holdings (TSX:CURA) is gaining entry into the Poland medical cannabis market.
In a news release, the company stated that its subsidiary, Curaleaf International, has acquired Can4Med, a pharmaceutical wholesaler that specializes in cannabinoid medications.
The acquisition puts Curaleaf Holdings and its subsidiary in a strong position to bolster patient access to high-quality medical cannabis products across Europe.
“This acquisition represents a significant step forward for Curaleaf International. Poland’s medical cannabis market is expanding rapidly, and our partnership with Can4Med allows us to better serve patients while driving growth across Europe,” Matt Darin, CEO of Curaleaf Holdings, said in a statement.
The Polish Pharmaceutical Chamber estimates the potential number of medical cannabis users could reach 300,000, while the number of legal cannabis users could be expected to reach 1.3 million by 2026.
Can4Med specializes in the acquisition, registration and distribution of medical cannabis and products containing THC and other cannabinoids in Poland
Curaleaf International is a subsidiary of Curaleaf Holdings and is one of Europe’s largest vertically integrated cannabis companies.
Curaleaf Holdings has a suite of brands under its belt, including Curaleaf, Select and Grassroots that provide industry-leading service, product selection and accessibility across the medical and adult use markets.
Shares of Curaleaf Holdings are up 4.93 per cent to C$7.66 as of 11:47 am ET.
Join the discussion: Find out what everybody’s saying about this stock on the Curaleaf Holdings Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.